Commonwealth Diagnostics International, Inc. (CDI), is a global diagnostics service provider, independent clinical laboratory, and medical technology company founded on the value-centric principle that efficient and early diagnosis of common gastrointestinal ailments results in optimal preventative healthcare, empowered providers and patients, better patient outcomes, and robust cost savings for the healthcare delivery system. CDI operates out of a new CLIA laboratory in Salem, Massachusetts, and specializes in providing innovative diagnostic products and services that support healthcare providers and their patients in the detection and management of some of the most common gastrointestinal disorders, including: hydrogen and methane breath testing for small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption, an ELISA blood test (IBSchek™) for irritable bowel syndrome (IBS), and AbStats™, an easy-to-use, non-invasive, 510(k) cleared digestive telemetry and sensory system.
CDI focuses on creating simple, accessible, and innovative approaches to diagnostic modalities while leading in categories of quality, accuracy, and scientific and clinical integrity. CDI is committed to be the “go-to” player in functional GI diagnostics, both in the delivery of our current test portfolio and in our commitment to contributing to research and development in the field. For more information, please email us at firstname.lastname@example.org or visit www.commdx.com.
39 Norman Street
Salem, Massachusetts 01970